New hope for blood cancer patients: experimental combo challenges Decades-Old treatment
NCT ID NCT06068621
Summary
This study tested whether adding the drug venetoclax to a specific chemotherapy regimen (CACAG) works better than the standard '3+7' chemotherapy for people newly diagnosed with acute myeloid leukemia (AML). It involved 200 participants aged 14-75 and aimed to see if the new combination leads to more people responding to treatment and living longer, while checking for safety. The goal is to improve control of this aggressive blood cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, 100853, China
Conditions
Explore the condition pages connected to this study.